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Abstract 
Chemoresistance is a major therapeutic challenge to overcome in NSCLC, in order to improve the 
current survival rates of <15% at 5 years. We and others have shown increased PI3K signalling in 
NSCLC to be associated with a more aggressive disease, and a poorer prognosis. In this study, 
targeted inhibition of three strategic points of the PI3K-NFκB axis was carried out with the aim of 
exploiting vulnerabilities in cisplatin resistant NSCLC cells. Cisplatin resistant cell lines were 
previously generated through prolonged exposure to the drug. Expression of PI3K and NFκB pathway 
related genes were compared between cisplatin resistant cells and their matched parent cells using a 
gene expression array, qRT-PCR, DNA sequencing, Western blot and immunofluorescence. Targeted 
inhibition was carried out using GDC-0980, a dual PI3K-mTOR inhibitor currently in Phase II clinical 
trials in NSCLC, and DHMEQ, an inhibitor of NFB translocation which has been used extensively 
both in vitro and in vivo. Effects of the two inhibitors were assessed by BrdU proliferation assay and 
multiparameter viability assay. NFKBIA was shown to be 12 fold overexpressed in cisplatin resistant 
cells, with no mutations present in exons 3, 4 or 5 of the gene. Corresponding overexpression of IκBα 
was also observed. Treatment with DHMEQ (but not GDC-0980) led to significantly enhanced effects 
on viability and proliferation in cisplatin resistant cells compared to parent cells. We conclude that 
NFκB inhibition represents a more promising strategy than PI3K-mTOR inhibition for treatment in 
the chemoresistance setting in NSCLC.  
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Introduction 
 
Lung cancer is the most common cause of cancer related deaths worldwide.
1
 Non Small Cell 
Lung Cancer (NSCLC) is defined as any form of epithelial lung carcinoma other than small 
cell lung carcinoma. This accounts for 80% of lung cancers 
2
 and includes large cell 
carcinoma, squamous cell carcinoma and adenocarcinoma. Despite advances in anti-cancer 
therapies the overall 5 year survival for lung cancer patients remains poor (<15%).  
 
The main anti-cancer treatment for NSCLC is platinum-based chemotherapy with either 
cisplatin or carboplatin in combination with a secondary agent such as paclitaxel or 
docetaxel. Chemotherapy is used in the post-operative, adjuvant setting and concurrently with 
radiotherapy for the radical treatment of locally advanced unresectable disease to increase 
long-term survival by ~5-10% at five years. 
 
The efficacy of cisplatin treatment is often limited by intrinsic or acquired resistance to the 
drug.  Many possible mechanisms of cisplatin resistance have been shown in various cell 
lines, and recent in vivo work has further elucidated the basis of resistance to this drug. The 
major mechanisms of resistance are (i) increased influx / decreased influx of cisplatin, (ii)  
elevated levels of glutathione, (iii) increased DNA repair and (iv) activation of signal 
transduction pathways e.g. MAPK, AKT, NFκB. 3-5  
 
Phosphatidylinositol 3-kinases (PI3Ks) were discovered by Lewis Cantley and colleagues, 
who first published on their association with the polyoma middle T protein in 1985.
6
 The 
signals that PI3K family members help to potentiate induce the cell to grow, differentiate, 
proliferate, and help with survival, motility and intracellular trafficking. As such, these 
enzymes are strongly implicated in the development of malignant behavior as well as playing 
a role in resistance to chemotherapy and targeted therapies. 
 
Upon activation by growth factor stimulation of Receptor Tyrosine Kinases, G-Protein 
Coupled Receptors or RAS phosphorylation, PI3K phosphorylates PIP2 to produce PIP3. 
PIP3 propagates the signal by bringing PDK1 and AKT into close proximity, allowing PDK1 
to activate AKT by phosphorylation.
7
 AKT can then help the cell to display malignant 
characteristics in several ways. It promotes cell survival by inhibiting BAD and BAX, two 
proapoptotic Bcl2 family members. AKT also phosphorylates Mdm2, resulting in 
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antagonization of p53-mediated apoptosis, as well as negatively regulating forkhead 
transcription factors, resulting in reduced production of cell-death promoting proteins.
7
 AKT 
can also impede negative regulation of transcription factor NFκB by IκB, leading to an 
increase in transcription of antiapoptotic and pro-survival genes, coding for proteins such as 
the antiapoptotic Bcl-2 and Bcl-XL.
8 
One common mechanism of acquired resistance to cancer therapies involves the upregulation 
of pathways that promote cell survival and proliferation. It is therefore unsurprising that PI3K 
pathway activation, which results in the NFκB-mediated upregulation of various genes that 
promote this type of behavior, has been implicated in cisplatin resistance in ovarian cancer 
cells, where it was shown that treatment with the drug activated the PI3K pathway, and that 
inhibition of the pathway sensitized cells to the effects of cisplatin.
9
 More recently, activation 
of AKT and ERK have been associated with resistance to cisplatin in NSCLC 
10-12 
and 
SCLC,
13
 though more research is needed to fully elucidate the role of these pathways in 
cisplatin resistance in lung cancer. Research into NFκB, PI3K and PI3K-mTOR inhibitors in 
NSCLC has increased recently, with pre-clinical data showing promising results.
13-14
 
Targeting the PI3K-mTOR pathway has been studied extensively in oncology, with a wide 
range of inhibitors investigated in cancers including NSCLC.
15
 One such dual inhibitor is 
GDC-0980, which is currently in phase II trials for NSCLC and other tumor types.
16, 17 
NFκB family members function as homo- or hetero-dimers to activate and repress the 
transcription of a large number of genes controlling immunological processes as well as cell 
growth and proliferation and many other cellular processes. Some of these genes include pro-
survival factors such as Bcl2, vascular endothelial growth factors, and many other growth 
factors. In recent years the NFκB transcription factors have been studied extensively, and 
growing evidence suggests an important role for NFκB in various oncological processes. 
The IκB family plays a key role in regulating NFκB. IκB proteins consist of an N regulatory 
domain, a series of six or more ankyrin repeats, and a PEST domain near the C terminus. 
Interactions with NFκB are mediated by the ankyrin repeat domains.18 IκB proteins inhibit 
NFκB function by masking NFκB nuclear translocation signals, and sequestering the 
transcription factor in the cytosplasm (Figure 1). 
The most widely studied IκB family member is IκBα, which is encoded by NFKBIA. In order 
to allow NFκB to function, signaling molecules such as AKT activate IκB kinase 1 (IKK1), 
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which phosphorylates IκBα on serines 32 and 36. This targets the protein for degradation in 
the ubiquitin proteasome, thus allowing the dissociation and translocation of NFκB to the 
nucleus.
19
 In the nucleus, NFκB activates the transcription of κB dependent genes, one of 
which is IκBα. Newly synthesized IκBα is responsible for post-induction repression of NFκB, 
through the removal of NFκB from DNA, and transportation of the transcription factor back 
to the cytoplasm.
20
 Mutations in the IκBα gene have been reported in Hodgkin/Reed-
Sternberg cells resulting in overexpression of a C-terminally truncated protein and 
constitutive activation of NFκB. 21, 22 
In cancer cells, NFκB has been shown to act in an anti-apoptotic, pro-proliferative manner. 
As such, inhibition of NFκB has been investigated in various types of cancer as a potential 
therapeutic intervention strategy. One such inhibitor is Dehydroxymethylepoxyquinomicin 
(DHMEQ), which prevents translocation of NFκB to the nucleus. Derived from the antibiotic 
epoxyquinomycin C, DHMEQ is a specific inhibitor of NFkB nuclear translocation,
23
 which 
has shown both anti-inflammatory effects and anti-tumour effects in multiple cancer types 
both in vitro and in vivo.
24-31
 
Here we investigate the effect of targeting key signaling molecules within the PI3K/NFkB 
pathway in two in vitro models of cisplatin resistant NSCLC.  
 
Results: 
An RT2 Profiler array (SABiosciences) was used to quantify the expression of 84 genes 
associated with the PI3K-Akt pathway and to identify any differences in mRNA expression 
between the H460 parent and H460CR cell lines. NFKBIA displayed an 11.99 fold 
upregulation in H460CR cells (Figure 2a, b). 4 genes were upregulated greater than 2 fold 
and 11 genes were downregulated greater than 2 fold in cisplatin resistant cells compared to 
parent cells. Of particular interest was NFKBIA as it displayed the highest differential 
expression between parent & resistant cell lines. This result was validated by QPCR using 
primers specific to NFKBIA, which identified 10.56 fold upregulation of NFKBIA in 
H460CR cells (Figure 2c).  
The gene product of NFKBIA, IκBα was then compared in H460 parent (Figure 3a) and 
H460 cisplatin resistant cells (Figure 3b), IκBα was shown to be more highly expressed in 
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H460CR cells than H460PT cells by analysis of immunofluorescence (Figure 3c) and 
Western blotting (Figure 3d, 3). IκBα was also shown to be more highly expressed in 
A549CR cells than A549PT cells by densitometry analysis of Western blots (Figure 3d, 3). 
A point mutation in exon 5 of NFKBIA has been previously identified which results in a 
truncated form of the protein IκBα, which cannot bind and inhibit NFκB.21, 22 Exons 3, 4 and 
5 of NFKBIA were amplified via nested PCR and PCR products were visualized on an 
agarose gel (Figure 3a). These amplicons were then sequenced using the ABI3130 sequencer 
(Figure 3b). Sequences were compared to wild type sequences using BLASTN, with no 
mutations being found (Figure 3c). 
The effects of PI3K-mTOR inhibitor GDC-0980 on cell proliferation were analysed by BrdU 
assay. GDC-0980 was found to induce a reduction in proliferation in H460PT, H460CR, 
A549PT and A549CR cell lines. GDC-0980 treatment was significantly more effective at all 
doses in H460PT cells when compared to the H460CR cells. At the lowest dose (0.33μM), 
GDC-0980 treatment was significantly more effective in A549CR cells than A549PT cells, 
however at all other doses, there was a trend towards GDC-0980 treatment being more 
effective in A549PT cells than A549CR cells (Figure 5a). The effect of GDC-0980 on these 
four cell lines was further investigated by a multiparameter cell viability assay using HCA. 
Imaging of cells treated with GDC-0980 compared with untreated cells allowed for 
visualization of cellular damage induced by the drug (Figure 5b) which was then quantified 
by cell count using HCA software (Figure 5c). Cell count was significantly reduced in 
H460PT cells compared with H460CR cells in response to GDC-0980 treatment at all doses. 
There was no significant difference in cell count between A549PT and A549CR cells (Figure 
5 b,c). 
The effects of NFκB translocation inhibitor DHMEQ on cell proliferation were analyzed by 
BrdU assay. DHMEQ was found to induce a reduction in proliferation in H460PT, H460CR, 
A549PT and A549CR cell lines. In contrast to the response to GDC-0980 treatment, 
DHMEQ treatment led to a significantly increased reduction of proliferation in cisplatin 
resistant cells compared to parent cells at all doses for A549 cells, and at higher doses for 
H460 cells (Figure 6). This increased efficacy of DHMEQ treatment in cisplatin resistant 
cells was also observed by multiparameter cell viability assay using HCA. Imaging of cells 
treated with DHMEQ compared with untreated cells allowed for qualitative observation of 
the significant difference in response between parent and cisplatin resistant cells (Figure 6b). 
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This difference in response was quantified by cell count using HCA software. Cell count was 
significantly reduced in cisplatin resistant H460 and A549 cells compared with matched 
parent cells at noted concentrations (Figure 6c).  
 
Discussion 
Activation of the PI3K/NfKB pathway has been shown previously to play a role in cisplatin 
resistance in ovarian cancer.
3
 As such, In-depth gene expression analysis of matched cisplatin 
sensitive (H460P) and cisplatin resistant (H460CR) cell lines was carried out using the 
human PI3K-AKT Signaling Pathway RT2 profiler array. Of the 84 genes quantified only 4 
upregulated genes, including an 11.99 fold increase in NFKBIA (gene encoding IκBα) 
expression, were identified in H460CR cells in comparison to H460 cells. Significant 
upregulation of NFKBIA in the H460CR cell line was validated by a gene specific 
qPCRassay. Investigation of IκBα expression at the protein level was carried out via 
immunofluorescence and Western blot. Immunofluorescence imaging indicated increased 
levels of IκBα in H460 cisplatin resistant cells compared to H460 parent cells. Western blot 
analysis indicated higher levels of IκBα in both H460 and A549 cisplatin resistant cells 
compared to their respective parent cell lines. Such activated levels of this negative regulator 
of NFkB in both chemoresistant models implies that IκBα could play a role in cisplatin 
resistance in NSCLC.  
It has been shown previously that truncated forms of the IκBα protein resulted in reduced 
IκBα–NFkB binding and prevention of post-induction repression of NFkB. Deregulated IκBα 
results in constitutive NFkB activity and the emergence of a chemoresistant phenotype due to 
upregulation of survival and anti-apoptotic genes transcriptionally regulated by NFkB. 
NFKBIA exons 3, 4 and 5 are the most common sites for deletions and mutations which 
result in truncated forms of the IκBα protein.21, 22, 33 Here we screened these exons, in H460 
parent and resistant cells, for the presence of mutations by Sanger sequencing. These 
sequences were compared to wild-type sequences using BLASTN. No mutations or deletions 
were detected.  
In order to assess the viability of targeting the PI3K pathway as a second line treatment in 
NSCLC, we investigated the effects of targeted inhibition on two strategic points in the PI3K-
NFκB pathway in parent and cisplatin resistant cells. Firstly, treatment with GDC-0980, a 
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dual PI3K-mTOR inhibitor, led to significantly reduced proliferation and viability in parent 
H460 cells compared to their matched cisplatin resistant cells. This is unsurprising due to the 
11 upstream PI3K pathway genes which were seen to be more highly expressed in parent 
cells than cisplatin resistant cells on the gene expression array. This data demonstrates that 
while the PI3K pathway maybe a potential therapeutic target in H460P cells the H460CR cell 
lines are less reliant on this pathway. GDC-0980 was not as effective in the A549PT cells and 
this may be due in part to the fact that these cells are PIK3CA mutation negative whereas the 
H460PT cells harbor a PIK3CA mutation. In both A549PT and A549CR cells, a similar trend 
in proliferation and cell viability was observed at higher concentrations of the drug, while at 
the lowest concentrations a significantly increased effect on proliferation in cisplatin resistant 
cells was observed. As such, we believe that direct inhibition of PI3K-mTOR may not be a 
useful strategy in this setting.  
We hypothesize based on our initial protein expression data that a deregulated IκBα/NFκB 
interaction may play a significant role in cisplatin resistance in our NSCLC models therefore 
we investigated the effect of targeting this aberrant IκBα/NFκB pathway. To this end we 
examined the effect of a specific inhibitor of NFκB translocation and binding, DHMEQ, in 
our cisplatin resistant models. This inhibitor, a derivative of the antibiotic epoxyquinomicin 
C, has shown promise as a treatment for rheumatoid arthritis as well as being effective in 
suppressing hormone-refractory prostate cancer in an in vivo model without any toxicity and 
is currently being progressed towards clinical trials.
27-29
 A dose-response proliferation assay 
and a multiparameter HCA viability assay were carried out using H460 and A549 parent and 
cisplatin resistant cell lines. In both models of resistance DHMEQ induced a reduction in 
proliferation to a significantly greater extent in the cisplatin resistant cell lines than in parent 
cell lines. These data further highlight that a deregulated IκBα/NFκB interaction may play a 
key role in cisplatin resistance in NSCLC cell lines. We hypothesize that inhibition of NFκB 
or its downstream targets may be an ideal strategy to resensitize cisplatin resistant cells to 
cisplatin.  
Further investigations to elucidate the exact mechanism involved in these IκBα activated 
resistant cells as well as cisplatin and DHMEQ combination treatment are warranted both in 
vitro and in vivo. Based on these data, we believe that a non-toxic specific inhibitor of NFκB 
such as DHMEQ may play a key role in future treatment of NSCLC patients with either 
intrinsic or acquired cisplatin resistance.  
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This study was carried out on the basis of previous published evidence supporting a role for 
the PI3K-NFκB axis in cisplatin resistance, 3, 9-13 with the aim of identifying strategic points 
within this pathway to target in order to overcome this resistance in NSCLC. With this 
promising data implying a major role for IκBα/NFκB interaction in NSCLC cisplatin 
resistance, inhibition of NFκB by DHMEQ or other targeted inhibitors could provide a 
beneficial treatment strategy for NSCLC patients who progress on cisplatin. We believe this 
data underpins the importance of determining which point in a signaling cascade is critical to 
therapeutic targeting, in order to ensure maximal benefit in specific clinical settings such as 
chemoresistance.  
Materials & Methods: 
Cell culture:  
H460 cells were grown in RPMI1640 media (Lonza) supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C and 5% CO2. A549 cells were grown in Ham’s F-12 media 
(Lonza) supplemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine at 
37°C and 5% CO2. Cisplatin resistant cell lines had previously been developed in this 
laboratory via continuous exposure of H460 and A549 cells to cisplatin.
32
 H460 parent cells 
(H460PT) could then be compared to H460 cisplatin resistant cells (H460CR), and A549 
parent cells (A549PT) could be compared to A549 cisplatin resistant cells (A549CR). 
Gene Expression Array:  
RNA was isolated from parent and resistant cell lines using TriReagent. Two RT2 Profiler 
PCR arrays were used (SABiosciences PI3K – AKT pathway array: PAHS-058). One 96 well 
array was carried out for H460PT RNA and the other for H460CR RNA. cDNA was added to 
RT2 qPCR Master Mix, which contains SYBR Green and reference dye. The experimental 
cocktail of cDNA, Master Mix and H2O was added to the 96 well array (25μl per well). Real 
time PCR thermal cycling was performed using the ABI 7500 thermal cycler. Changes in 
gene expression between H460PT and H460CR cell lines were analyzed using 
SABiosciences online software which incorporates the ΔΔCT method. 
qRT-PCR: 
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qRT-PCR validation of array results was carried out for NFKBIA. Roche FastStart Universal 
SYBR green master (Rox) was used with cDNA prepared from H460PT and H460CR cells. 
NFKBIA and β-actin -specific primers were used (SABiosceinces).  
NFKBIA nested PCR  
Nested PCR was carried out for exons 3, 4 and 5 of the NFKBIA gene. In the first PCR 
reaction, forward primers were used. In the second PCR reaction, inner forward primers were 
used. For both reactions, the same reverse primers were used. Primer sequences and 
annealing temperatures are shown in Table 1 as adapted from.
31
 The nested PCR Products 
were run on a 1% agarose gel with 1X TBE buffer. A 100bp DNA ladder was used to 
determine the size of the amplicons. PCR product purification was carried out using a 
QIAquick PCR Purification Kit (Qiagen). The DNA was purified according to the 
manufacturer’s protocol, using the buffers and spin columns provided. The purified DNA was 
eluted in 30µl Buffer EB. Cycle sequencing was then performed using BigDye Terminator 
v3.1. Each reaction contained 1µl primer, 3µl BigDye terminator mix v3.1, 50ng template 
DNA and dH2O to a total volume of 20µl. A control tube contained 1µl pGem, 2µl M13 
primer, 3µl BigDye terminator mix v.3.1 and 14µl dH2O. The tubes were then placed in the 
GeneAmp 2400 thermal cycler using the following program: Step 1: 96ºC for 1 minute, step 
2: 96ºC for 10 minutes, step 3: 50ºC for 5 seconds, step 4: 60ºC for 4 minutes, step 5: repeat 
steps 2-4, 25 times, step 6: go to 4ºC. The sequencing products were then cleaned using 
DyeEx spin columns (Qiagen). The clean-up was carried out as per the manufacturer’s 
protocol, and the recovered reaction was dried using a speedy vac at medium heat until dry. 
The pellet was then resuspended in 10µl HiDiformamide, and loaded onto an ABI 96 well 
plate. The plate was then placed on the AB3130 sequencing platform which read the 
sequences. 
Western Blot: 
Protein was isolated from H460PT, H460CR, A549PT and A549CR cells using RIPA buffer 
supplemented with sodium orthovandate (50mM), PMSF (100mM), protease inhibitor 
cocktail, β-glycerophosphate (500mM) and sodium fluoride (500mM). 30µg total protein 
from each cell line was loaded onto a 12% acrylamide-SDS gel. Proteins were resolved by 
electrophoreisis and transferred onto a PVDF membrane.  IκBα was detected using a rabbit 
IκBα (N terminal) antibody (Cell Signaling). Membranes were probed as per manufacturer’s 
protocol. Bound antibody complexes were detected using the Supersignal West Pico 
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Chemiluminescent substrate kit (Pierce). The membrane was then exposed to scientific 
imaging X-ray film and developed. 
Immunofluorescence: 
Expression levels of IκBα in H460 and A549 parent and cisplatin resistant cell lines were also 
investigated at the protein level by Immunofluorescence using High Content Analysis (HCA) 
imaging. Cells were seeded in 96 well plates and either pretreated with TNFα (25ng/ml for 
20mins) or left untreated, then fixed with 4% PFA for 15 minutes at RT. Cells were 
subsequently blocked in blocking buffer (100μl per well, 1X PBS containing 5% normal goat 
serum and 0.3% Triton X-100, Sigma) at room temperature for 60 minutes.  
The blocking solution was aspirated, and diluted primary antibody was added to each well 
(100μl per well, 1X PBS containing 1% BSA, 0.3% Triton X-100 and 0.8% IκBα antibody). 
The plate was incubated at 4ºC overnight. 
Cells were washed 3 times for 5 minutes each in PBS (100μl), and then incubated with Alexa 
Fluor 488 conjugated goat-anti-mouse secondary antibody (invitrogen) for 1 hour at room 
temperature in the dark. Cells were washed 3 times for 5 minutes each in PBS (100μl), and 
then stained with Höechst nuclear stain (bisbenzimide H33348, Fluka Biochemika, 4µM, 20 
mins). 100μl PBS was finally added to all 96 wells of the plate for imaging.  
The cells were imaged using the InCell Analyzer1000 (GE Lifesciences) and images were 
analyzed using the High Content Analyzer software, which quantified the intensity of green 
fluorescence in the cytosol and nucleus for untreated and TNFα treated cells.  
Proliferation: 
Cells were treated with either GDC-0980 (Genentech) or DHMEQ (Umezawa lab) at noted 
concentrations for 72 hours in 96 well plates at 37°C and 5% CO2. The Cell Proliferation 
ELISA, BrdU (colorimetric) kit (Roche) was used to assess percentage proliferation in 
relation to untreated cells. BrdU reagent was added directly to each well for the last 4 hours 
of treatment, allowing it to incorporate into the genome of proliferating cells. The cells were 
then fixed and exposed to an anti-BrdU antibody for 90 minutes before finally adding 
substrate and stop solutions as per manufacturer’s protocol. Absorbance was measured @ 
595nm by a spectrophotometer to quantify corresponding alterations in proliferation. 
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Multiparameter High Content Analysis Assay 
Cells were treated with either GDC-0980 or DHMEQ at noted concentrations for 24 hours in 
96 well plates at 37°C and 5% CO2. Cells were stained simultaneously with Höechst nuclear 
stain (bisbenzimide H33348, FlukaBiochemika, 1µM, 30 min) and mitotracker red 
mitochondrial stain (invitrogen, 0.5µM, 30 min), then washed in PBS and fixed in PFA (4%, 
10 min), before permeablising (0.5% Triton-X-100 in PBS) and finally staining with Alexa Fluor 
488 Phalloidin (invitrogen, 10µM, 30 min). The cells were imaged using the InCell 
Analyzer1000 (GE Lifesciences) and images were analyzed using High Content Analysis 
(HCA) software, which quantified cell count.  
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Figure 1. PI3K signaling & inhibition 
PI3K-AKT-mTOR activation leads to regulation of proliferation, apoptosis, angiogenesis and 
other key cellular processes, through the transcription of hundreds of target genes by NFκB. 
Inactive NFκB is bound by its inhibitor IκBα in the cytoplasm, until activation leads to 
dissociation of the two proteins and proteosomal degradation of IκBα. NFκB is then free to 
translocate to the nucleus where it acts as a transcription factor. One of NFκB’s many target 
genes is IκBα, which removes NFκB from the nucleus, returning it to its original inactive 
form in the cytoplasm. GDC-0980 is a dual PI3K-mTOR inhibitor. DHMEQ is an inhibitor of 
NFκB translocation to the nucleus. AKT, Protein Kinase B; IκBa, Nuclear factor of kappa 
light polypeptide gene enhancer in B-cellsinhibitor, alpha; mTOR, mammalian target of 
rapamycin; NFκB, Nuclear factor kappa-light-chain-enhancer ofactivated B cells; PI3K, 
Phosphatidylinositide 3-kinase. 
 
 
Figure 2. NFKBIA is more highly expressed in H460CR cells than H460 cells  
An RT
2
 profiler PI3K-Akt pathway array was carried out to compare gene expression in H460 
(cisplatin sensitive) and H460CR (cisplatin resistant) cell lines.  
a) A heat map was constructed using SABiosciences online software, corresponding to table A. 4 
genes were upregulated greater than 2 fold and 11 genes were downregulated greater than 2 fold 
in cisplatin resistant cells compared to parent cells. Position E01 corresponds to an increase in 
NFKBIA. 
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b) Upregulation of NFKBIA in H460CR cells was validated by QRTPCR, using NFKBIA and ACTB 
specific primers, in three independent experiments. Fold regulation is shown for NFKBIAin 
H460CR cells compared to H460PT cells, calculated via the ΔΔCt method. 
***p< 0.001  
 
 
Figure 3. IkBa is more highly expressed in H460CR cells than H460parent cells. 
a) Immunofluorescence image: H460 parent untreated cells were stained with IκBα primary 
antibody and Alexa Fluor488 conjugated secondary antibody (green). Cells were also stained with 
Höechst nuclear stain (blue). Alexa Fluor conjugated secondary antibody (green) indicates IκBα 
expression in the cytoplasm and peri-nuclear space.  
b) Immunofluorescence image: H460CR untreated cells were stained and imaged as in a). The 
increased intensity of green staining here indicates the presence of more IκBα here than in H460 
cells. 
c) Immunofluorescence analysis: Cells were either left untreated (as in a and b) or pretreated with 
TNAα (25ng/ml) for 20 minutes. Cells were imaged using High Content Analysis. Each treatment 
was carried out in triplicate and three independent experiments were carried out. Cell intensity 
(amount of IκBα fluorescence) was measured in the nucleus and the cytpolasm using HCA 
software. 
d) H460 and A549 parent and cisplatin resistant cell protein samples were run on an SDS-PAGE gel 
&analyzed by Western blot three independent times for expression of IκBα and αβTubulin. 
e) Densitometry analysis was carried out using ImageJ software to compare expression of IκBα 
between H460 and A549 parent and cisplatin resistant cells. 
*p< 0.05 ***p< 0.001  
 
 
Figure 4. NFKBIA Sequence Trace 
a) Exons 3, 4 and 5 of IκBα were amplified via nested PCR from H460PT and H460CR RNA. PCR 
products were visualized on a 1% agarose gel, and compared to a 100bp DNA ladder (Fermentas).  
b) Amplicons were sequenced using the AB3130 sequencer. Sequence trace files were obtained for 
each exon in each cell line, an example of which is shown here. No double peaks were observed 
in any trace file.  
c) Forward and reverse sequences were compared against wild-type sequences for each NFKBIA 
exon in both cell lines using the basic local alignment search tool for nucleotides (BLASTN). No 
discrepancies were identified between our sequences and wild-type sequences. A sample 
sequence of H460 NFKBIA exon 3 is shown here, aligned with wild type IκBα exon 3. 
 
 
Figure 5:  The effects of GDC-0980 treatment on proliferation and cell viability in H460 
parent and cisplatin resistant cells. 
a) H460 and parent and cisplatin resistant cells were treated in triplicate at noted concentrations of 
GDC-0980 for 72 hours. Cells were analysed via BrdU assay (n=3). Percentage proliferation is 
shown here. 
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b) Sample image: Cells were stained with Höechst blue nuclear stain, mitotracker red mitochondrial 
stain and phalloidin green F-actin stain, and imaged using the In Cell Analyser 1000. 
c) H460 and parent and cisplatin resistant cells were treated in triplicate at noted concentrations of 
GDC-0980 for 48 hours. Eight fields were imaged per well at 10x magnification using the In Cell 
Analyser 1000. 
d) Images from c) were analyzed using In Cell software which identified cell count automatically 
from nuclear staining.  
*p< 0.05 **p< 0.005 ***p< 0.001 
 
Figure 6:  The effects of DHMEQ treatment on proliferation and cell viability in H460 parent 
and cisplatin resistant cells. 
a) H460 and parent and cisplatin resistant cells were treated in triplicate at noted concentrations of 
DHMEQ for 72 hours. Cells were analyzed via BrdU assay (n=3). Percentage proliferation is 
shown here. 
b) H460 and parent and cisplatin resistant cells were treated in triplicate at noted concentrations of 
DHMEQ for 48 hours. Cells were stained with Höechst blue nuclear stain, mitotracker red 
mitochondrial stain and phalloidin green F-actin stain, and imaged using the In Cell Analyser 
1000. Eight fields were imaged per well at 10x magnification. 
c) Images from b) were analyzed using In Cell software which identified cell count automatically 
from nuclear staining.  
*p< 0.05 **p< 0.005 ***p< 0.001 
 
 
Table 1.             NFKBIA
a
 primers used in this study 
Oligo Name  Sequence (5’ → 3’) Tm(°C) 
NFKBIA Exon 3 Forward Outer  CCTGTCTAGGAGGAGCAGCAC (21) 63.7 
NFKBIA Exon 3 Reverse  AAAGGCATCCAATAGGCAC (19) 54.5 
NFKBIA Exon 3 Forward Inner  AGGAGACACGGGTTGAGG (18) 58.2 
NFKBIA Exon 4 Forward Outer  GAACCCAGACTGTGGGTTCT (20) 59.4 
NFKBIA Exon 4 Reverse  TGAGATGCTTATGGCTGCA (19) 54.5 
NFKBIA Exon 4 Forward Inner  AGGTGAAAGGAGTGAGGGTTG (21) 59.8 
NFKBIA Exon 5 Forward Outer  ATGCTCAGGTTGGTGCTTCC (20) 59.4 
NFKBIA Exon 5 Reverse  CTGGGAGGGTGAAAGGGAAT (19) 58.8 
NFKBIA Exon 5 Forward Inner  GCACTGAGTCAGGCTCCTCG (20) 63.5 
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aNFKBIA (IκBα): Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha. Primers were used as published in [25]. 
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